• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Resources

      For healthcare professionals

      BOTOX® Dosage and Administration Guide

      This guide provides information on the recommended dosage and administration of BOTOX® for chronic migraine. The recommended position for injection sites and additional information specific to each indication is also included, along with important safety information.

      To receive a copy of this guide, please, submit your details on the Contact Us page and tick BOTOX® Dosage and Administration Guide.

      BOTOX® Injection Site Anatomy Poster with Muscles and Nerves

      This poster shows a summary of the PREEMPT treatment paradigm, a culmination of over 10 years’ experience of migraine research, optimised to help patients with chronic migraine maximise their likelihood of a beneficial effect. 

      To receive a copy of this poster, please submit your details on the Contact Us page and tick BOTOX® Injection Site Anatomy Poster with Muscles and Nerves.


      Resources for your patients

      Patient Guide for the Treatment of Chronic Migraine with BOTOX®

      To support your chronic migraine patients treated with BOTOX®, this guide provides information on how the treatment works, what to expect during and after treatment and potential side-effects.

      The information in this guide does not replace the Patient Information Leaflet (PIL) that is enclosed with the prescribed medication.

      To receive a copy of this guide, please submit your details on the Contact Us page and tick Chronic Migraine Patient Guide.


      CM: chronic migraine.

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. Allergan Ltd. Data on file 014
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed April 2022

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: April 2022. UK-BCM-220080.